Drug interactions with herbal products and grapefruit juice: A conference report

Shiew Mei Huang, Stephen D. Hall, Paul Watkins, Lori A. Love, Cosette Serabjit-Singh, Joseph M. Betz, Freddie Ann Hoffman, Peter Honig, Paul M. Coates, Jonca Bull, Shaw T. Chen, Gregory L. Kearns, Michael D. Murray

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Drug interactions with herbal products and food are an evolving knowledge base. Recent examples of protease inhibitors and St John's wort provide compelling evidence of the necessity of adequate pharmacovigilance in ascertaining heretofore unanticipated but preventable drug-herbal interactions. Clinical pharmacology studies of potential significant interactions in phase 1 and phase 2 trials, as well as phase 3 trials, will require a heightened awareness of possible herbal product usage by patients and consumers in the intended study population. Ultimately, better mechanisms are needed to encourage communication among patients and physicians about dietary supplements and, in particular herbal drug and food interactions. Patients whose current prescription regimens do not provide complete symptomatic relief are study populations likely to use supplemental herbal products. Such patient populations might include those with cancer, persistent pain, and other refractory long-term diseases. Drug development study protocols, as well as postmarketing risk assessments, are needed to maintain a high level of alertness to potential drug and food interactions and manage patient risk.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalClinical Pharmacology and Therapeutics
Volume75
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Herb-Drug Interactions
Citrus paradisi
Food-Drug Interactions
Population
Pharmacovigilance
Knowledge Bases
Clinical Pharmacology
Dietary Supplements
Protease Inhibitors
Prescriptions
Communication
Physicians
Food
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Drug interactions with herbal products and grapefruit juice : A conference report. / Huang, Shiew Mei; Hall, Stephen D.; Watkins, Paul; Love, Lori A.; Serabjit-Singh, Cosette; Betz, Joseph M.; Hoffman, Freddie Ann; Honig, Peter; Coates, Paul M.; Bull, Jonca; Chen, Shaw T.; Kearns, Gregory L.; Murray, Michael D.

In: Clinical Pharmacology and Therapeutics, Vol. 75, No. 1, 01.01.2004, p. 1-12.

Research output: Contribution to journalArticle

Huang, SM, Hall, SD, Watkins, P, Love, LA, Serabjit-Singh, C, Betz, JM, Hoffman, FA, Honig, P, Coates, PM, Bull, J, Chen, ST, Kearns, GL & Murray, MD 2004, 'Drug interactions with herbal products and grapefruit juice: A conference report', Clinical Pharmacology and Therapeutics, vol. 75, no. 1, pp. 1-12. https://doi.org/10.1016/j.clpt.2003.07.002
Huang, Shiew Mei ; Hall, Stephen D. ; Watkins, Paul ; Love, Lori A. ; Serabjit-Singh, Cosette ; Betz, Joseph M. ; Hoffman, Freddie Ann ; Honig, Peter ; Coates, Paul M. ; Bull, Jonca ; Chen, Shaw T. ; Kearns, Gregory L. ; Murray, Michael D. / Drug interactions with herbal products and grapefruit juice : A conference report. In: Clinical Pharmacology and Therapeutics. 2004 ; Vol. 75, No. 1. pp. 1-12.
@article{04c45d26ad5e4940a5441a27d5372a2d,
title = "Drug interactions with herbal products and grapefruit juice: A conference report",
abstract = "Drug interactions with herbal products and food are an evolving knowledge base. Recent examples of protease inhibitors and St John's wort provide compelling evidence of the necessity of adequate pharmacovigilance in ascertaining heretofore unanticipated but preventable drug-herbal interactions. Clinical pharmacology studies of potential significant interactions in phase 1 and phase 2 trials, as well as phase 3 trials, will require a heightened awareness of possible herbal product usage by patients and consumers in the intended study population. Ultimately, better mechanisms are needed to encourage communication among patients and physicians about dietary supplements and, in particular herbal drug and food interactions. Patients whose current prescription regimens do not provide complete symptomatic relief are study populations likely to use supplemental herbal products. Such patient populations might include those with cancer, persistent pain, and other refractory long-term diseases. Drug development study protocols, as well as postmarketing risk assessments, are needed to maintain a high level of alertness to potential drug and food interactions and manage patient risk.",
author = "Huang, {Shiew Mei} and Hall, {Stephen D.} and Paul Watkins and Love, {Lori A.} and Cosette Serabjit-Singh and Betz, {Joseph M.} and Hoffman, {Freddie Ann} and Peter Honig and Coates, {Paul M.} and Jonca Bull and Chen, {Shaw T.} and Kearns, {Gregory L.} and Murray, {Michael D.}",
year = "2004",
month = "1",
day = "1",
doi = "10.1016/j.clpt.2003.07.002",
language = "English (US)",
volume = "75",
pages = "1--12",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Drug interactions with herbal products and grapefruit juice

T2 - A conference report

AU - Huang, Shiew Mei

AU - Hall, Stephen D.

AU - Watkins, Paul

AU - Love, Lori A.

AU - Serabjit-Singh, Cosette

AU - Betz, Joseph M.

AU - Hoffman, Freddie Ann

AU - Honig, Peter

AU - Coates, Paul M.

AU - Bull, Jonca

AU - Chen, Shaw T.

AU - Kearns, Gregory L.

AU - Murray, Michael D.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Drug interactions with herbal products and food are an evolving knowledge base. Recent examples of protease inhibitors and St John's wort provide compelling evidence of the necessity of adequate pharmacovigilance in ascertaining heretofore unanticipated but preventable drug-herbal interactions. Clinical pharmacology studies of potential significant interactions in phase 1 and phase 2 trials, as well as phase 3 trials, will require a heightened awareness of possible herbal product usage by patients and consumers in the intended study population. Ultimately, better mechanisms are needed to encourage communication among patients and physicians about dietary supplements and, in particular herbal drug and food interactions. Patients whose current prescription regimens do not provide complete symptomatic relief are study populations likely to use supplemental herbal products. Such patient populations might include those with cancer, persistent pain, and other refractory long-term diseases. Drug development study protocols, as well as postmarketing risk assessments, are needed to maintain a high level of alertness to potential drug and food interactions and manage patient risk.

AB - Drug interactions with herbal products and food are an evolving knowledge base. Recent examples of protease inhibitors and St John's wort provide compelling evidence of the necessity of adequate pharmacovigilance in ascertaining heretofore unanticipated but preventable drug-herbal interactions. Clinical pharmacology studies of potential significant interactions in phase 1 and phase 2 trials, as well as phase 3 trials, will require a heightened awareness of possible herbal product usage by patients and consumers in the intended study population. Ultimately, better mechanisms are needed to encourage communication among patients and physicians about dietary supplements and, in particular herbal drug and food interactions. Patients whose current prescription regimens do not provide complete symptomatic relief are study populations likely to use supplemental herbal products. Such patient populations might include those with cancer, persistent pain, and other refractory long-term diseases. Drug development study protocols, as well as postmarketing risk assessments, are needed to maintain a high level of alertness to potential drug and food interactions and manage patient risk.

UR - http://www.scopus.com/inward/record.url?scp=9144237410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144237410&partnerID=8YFLogxK

U2 - 10.1016/j.clpt.2003.07.002

DO - 10.1016/j.clpt.2003.07.002

M3 - Article

C2 - 14749688

AN - SCOPUS:9144237410

VL - 75

SP - 1

EP - 12

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -